Mandate

Vinge advises the Swedish National Debt Office in connection with a state credit guarantee for SAAB

February 24, 2010

Vinge has represented the Swedish government acting through the Swedish National Debt Office in connection with the state credit guarantee for SAAB Automobile’s loan of EUR 400 million from the European Investment Bank (EIB). The state guarantee agreement was entered into in conjunction with closing of Spiker Cars N.V.’s acquisition of all shares in SAAB. Saab and its new owners have provided pledges in various assets in Sweden as security for their obligations in accordance with the back-to-back agreement which Saab has entered into with the National Debt Office.

Vinge’s team included partners Maria-Pia Midenbäck Hope (responsible partner), Carl Gustav De Geer, Fabian Ekeblad and Per Eric Alvsing and associates Dan Hanqvist, Louise Brorsson Salomon, Nils Taro-Lock, Christina Olsson Rosén, Tina Hård and Sofia Berg as well as project assistant Bettina Gamba.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026